Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 3;42(5):112503. doi: 10.1016/j.celrep.2023.112503

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

XG005-CYLK is therapeutic against BA.2 and BA.5 in vivo

(A) In vitro ADE effects induced by both XG005 and its counterpart LY-CoV1404 (bebtelovimab). In vitro ADE assays were performed in the Raji cells by using luciferase-expressing SARS-CoV-2 pseudovirus. The presence of various dilutions of antibodies induced distinct levels of luciferase signal, while the luciferase signal without adding any antibody was almost zero.

(B) No ADE effect induced by the GRLR and LALA versions, but not the YTE version, of the Fc-engineered XG005 antibodies.

(C) Pharmacokinetics of single-dose mAbs, XG005, XG005-C109S-YTE-LALA-Kdel (XG005-CYLK), and LY-CoV1404 in transgenic mice, C57BL/6JSmoc, which expressed human neonatal Fc receptor (hFcRn).

(D) XG005 potently neutralizes authentic SARS-CoV-2 BA.2 and BA.5 viruses. The in vitro neutralization assays were repeated at least twice.

(E) Diagram of antibody treatment protocols for human ACE2 transgenic mice intranasally challenged with BA.2 or BA.5 viruses.

(F–G) Virus titers in lung tissues of mice collected 2 days after BA.2 (F) or BA.5 (G) viral infection. Data are presented as mean ± SD. Each group contains three to five individual mice.

See also Figures S7 and S8.